Illumina Inc (ILMN) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumab...
Illumina Inc (ILMN) currently trades at a P/E ratio of 40.25 (historical range: 11.53–41.16, median: 23.88), placing it at the 99th percentile — expensive relative to its history, P/S ratio of 7.82 (range: 2.58–7.99, 99th percentile — expensive relative to its history).
Over the historical period (2024-08-30 to 2026-08-28), Illumina Inc's P/E ratio has expanded by 109% over the observed period (from an average of 12.5 to 26.3).
Illumina Inc appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 40.25 | 11.53 | 23.88 | 41.16 | 99th | expensive relative to its history |
| P/S Ratio | 7.82 | 2.58 | 4.53 | 7.99 | 99th | expensive relative to its history |
| FCF Yield | 0.01 | 0.00 | 0.02 | 0.06 | 17th | expensive relative to its history |